CUE (Cue Biopharma) Marketable Securities: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CUE Cue Biopharma Inc CUE
59 GF Score
Price $31.46
GF Value $62.74
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cue Biopharma Marketable Securities?

Cue Biopharma CUE +2.18% 59 Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus rates CUE with a GF Score™ of 59/100 and a GF Value™ of $62.74 (Possible Value Trap). The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Cue Biopharma's Marketable Securities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Cue Biopharma  (NAS:CUE) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Cue Biopharma Marketable Securities Related Terms

Cue Biopharma Marketable Securities Historical Data

* Premium members only.

The historical data trend for Cue Biopharma's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cue Biopharma Marketable Securities Chart

Cue Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 24.68 0.00 0.00 0.00

Cue Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 6.97 0.00 0.00
CUE
59GF Score
Cue Biopharma Inc CUE
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cue Biopharma Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Cue Biopharma (CUE) has a Marketable Securities of $0.00 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Cue Biopharma and its competitors.
Is Cue Biopharma's Marketable Securities too high?
Cue Biopharma's current Marketable Securities is $0.00 Mil. Overall, Cue Biopharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's Marketable Securities compare to ALPS and AARD?
Cue Biopharma's Marketable Securities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Cue Biopharma and its competitors. Cue Biopharma's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (CUE) is currently considered Possible Value Trap. The stock's GF Value™ is $62.74, compared to a current price of $31.46 — trading 49.9% below its estimated fair value. The current Marketable Securities is $0.00 Mil. Cue Biopharma's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Cue Biopharma (CUE), the current Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cue Biopharma (CUE) Overvalued in 2026?

Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued. The current stock price of $31.46 is trading 49.9% below its estimated GF Value™ of $62.74. GuruFocus considers Cue Biopharma to be Possible Value Trap.

Key valuation signals for CUE:

  • Marketable Securities: $0.00 Mil
  • GF Value™: $62.74 vs. price of $31.46 (49.9% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cue Biopharma Business Description

Other Exchanges 1UC0:Germany
Address 40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
59GF Score

Get the complete analysis for CUE

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.46
Price
$62.74
GF Value